sp-8356
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 3, 2021 (NCT05574166)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- BasiginANTAGONIST
BSG antagonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(/C=C/C2=CC(=O)[C@H]3C[C@@H]2C3(C)C)cc(O)c1O- Mol. weight
- 300.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2426707 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05574166 | Phase 1 | Jan 3, 2021 | Quotient, Shin Poong Pharmaceuticals |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Quotient | For profit | 1 | 0 | 1 | 2021 |
| Shin Poong Pharmaceuticals | For profit | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1